Pancreatic Cancer Research

ResearcherNagoya UniversityActive in the last 2 years

Norifumi Hattori

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-1433-7208; OpenAlex author ID A5024000121. Sources: OpenAlex.

Their work

Papers
14
Trials
0
Grants
0
Labs led
0
Collaborators
18
Papers, trials and grants by year

2015: 1 paper · 2016: none · 2017: none · 2018: 4 papers · 2019: none · 2020: none · 2021: 2 papers · 2022: 2 papers · 2023: 3 papers · 2024: 1 paper · 2025: 1 paper

Papers 14

  1. Exploration of Lipid Mediators for Therapeutic Monitoring of Pancreatic Cancer Patients. Co-author DOI 10.21873/anticanres.17520↗
  2. Genome-wide microRNA Analysis Identified miR-210-3p Over-expression in Pancreatic Cancer Tissues as a Predictor of their Local Invasiveness. Co-author DOI 10.21873/anticanres.17297↗
  3. Predictive impacts of peritoneal washing cytology for surgical resection-intended pancreatic cancer cases: Establishment of planned staging laparoscopy criteri… Co-author DOI 10.1002/jhbp.1373↗
  4. Albumin-Globulin Ratio Indicates the Survival Outcome of Pancreatic Cancer Cases Who Underwent Preoperative Treatment and Curative Surgical Resection. Co-author DOI 10.1080/01635581.2023.2191384↗
  5. High Preoperative Serum D-dimer Predicts Unfavorable Survival Outcomes for Pancreatic Cancer Patients. Co-author DOI 10.21873/anticanres.16491↗
  6. Downregulation of ROBO4 in Pancreatic Cancer Serves as a Biomarker of Poor Prognosis and Indicates Increased Cell Motility and Proliferation Through Activation… Co-author DOI 10.1245/s10434-022-12039-5↗
  7. Comparison Between FOLFIRINOX and nal-IRI/FL as Second-line Treatment After Gemcitabine Plus Nab-paclitaxel for Pancreatic Cancer. Co-author DOI 10.21873/anticanres.15882↗
  8. Age-Related Differences in the Prognosis of Pancreatic Cancer According to Perioperative Systemic Therapy. Co-author DOI 10.1097/mpa.0000000000001712↗
  9. A Possible Definition of Oligometastasis in Pancreatic Cancer and Associated Survival Outcomes. Co-author DOI 10.21873/anticanres.15189↗
  10. Clinical Implications of Lysyl Oxidase-Like Protein 2 Expression in Pancreatic Cancer. Co-author DOI 10.1038/s41598-018-28253-9↗
  11. Comparison of the Survival Outcomes of Pancreatic Cancer and Intraductal Papillary Mucinous Neoplasms. Co-author DOI 10.1097/mpa.0000000000001110↗
  12. Prognostic Impact of Portal System Invasion in Pancreatic Cancer Based on Image Classification. Co-author DOI 10.1097/mpa.0000000000001186↗
  13. Effect of Plasma-Activated Lactated Ringer's Solution on Pancreatic Cancer Cells In Vitro and In Vivo. Co-author DOI 10.1245/s10434-017-6239-y↗
  14. Effectiveness of plasma treatment on pancreatic cancer cells. Co-author DOI 10.3892/ijo.2015.3149↗

Closest collaborators

The 18 strongest of 18 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yasuhiro Kodera · 14 shared papers, 2015–2025 · strength 1.70
  2. Mitsuro Kanda · 13 shared papers, 2015–2025 · strength 1.62
  3. Masamichi Hayashi · 12 shared papers, 2018–2025 · strength 1.58
  4. Nobutake Tanaka · 6 shared papers, 2018–2023 · strength 0.82
  5. Fuminori Sonohara · 6 shared papers, 2018–2025 · strength 0.70
  6. Tomohisa Otsu · 4 shared papers, 2022–2025 · strength 0.69
  7. Suguru Yamada · 8 shared papers, 2015–2022 · strength 0.67
  8. Nobuhiko Nakagawa · 2 shared papers, 2024–2025 · strength 0.40
  9. Tsutomu Fujii · 5 shared papers, 2015–2021 · strength 0.35
  10. Masaya Yamanaka · 2 shared papers, 2021–2022 · strength 0.24
  11. Haruyoshi Tanaka · 1 shared paper, 2025 · strength 0.22
  12. Masaya Suenaga · 3 shared papers, 2018 · strength 0.20
  13. Keizo Fujita · 1 shared paper, 2024 · strength 0.18
  14. Shinji Mii · 1 shared paper, 2022 · strength 0.12
  15. Yusuke Sato · 1 shared paper, 2018 · strength 0.08
  16. Akihiro Hirakawa · 1 shared paper, 2018 · strength 0.07
  17. Daishi Morimoto · 1 shared paper, 2018 · strength 0.06
  18. Hiroyuki Sugimoto · 1 shared paper, 2015 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.